DDInter1269 DDInter1826
Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may
A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Tolazamide
Nateglinide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Tolazamide
Nateglinide {u} (Compound) binds {v} (Gene) KCNJ11
KCNJ11 {u} (Gene) is bound by {v} (Compound) Tolazamide
Nateglinide {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Tolazamide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Sulfacetamide
Sulfacetamide {u} (Compound) resembles {v} (Compound) Tolazamide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Tolazamide
Nateglinide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Tolazamide
Nateglinide {u} (Compound) binds {v} (Gene) KCNJ11
KCNJ11 {u} (Gene) is bound by {v} (Compound) Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Tolazamide
Nateglinide {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Tolazamide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Probenecid
Probenecid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Tolazamide
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Tolazamide (Compound)
Nateglinide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Tolazamide (Compound)
Nateglinide (Compound) binds KCNJ11 (Gene) and KCNJ11 (Gene) is bound by Tolazamide (Compound)
Nateglinide (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Tolazamide (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Tolazamide (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound) and Tolbutamide (Compound) resembles Tolazamide (Compound)
Nateglinide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Tolbutamide (Compound) and Tolbutamide (Compound) resembles Tolazamide (Compound)
Nateglinide (Compound) binds KCNJ11 (Gene) and KCNJ11 (Gene) is bound by Tolbutamide (Compound) and Tolbutamide (Compound) resembles Tolazamide (Compound)
Nateglinide (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Tolbutamide (Compound) and Tolbutamide (Compound) resembles Tolazamide (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Probenecid and Probenecid may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Tolazamide (Compound)